BACKGROUND AND PURPOSE: The development of subtype-selective ligands to inhibit voltage-sensitive sodium channels (VSSCs) has been attempted with the aim of developing therapeutic compounds. Tetrodotoxin (TTX) is a toxin from pufferfish that strongly inhibits VSSCs. Many TTX analogues have been identified from marine and terrestrial sources, although their specificity for particular VSSC subtypes has not been investigated. Herein, we describe the binding of 11 TTX analogues to human VSSC subtypes Nav 1.1-Nav 1.7. EXPERIMENTAL APPROACH: Each VSSC subtype was transiently expressed in HEK293T cells. The inhibitory effects of TTX analogues on each subtype were assessed using whole-cell patch-clamp recordings. KEY RESULTS: The inhibitory effects of TTX on Nav 1.1-Nav 1.7 were observed in accordance with those reported in the literature; however, the 5-deoxy-10,7-lactone-type analogues and 4,9-anhydro-type analogues did not cause inhibition. Chiriquitoxin showed less binding to Nav 1.7 compared to the other TTX-sensitive subtypes. Two amino acid residues in the TTX binding site of Nav 1.7, Thr1425 and Ile1426 were mutated to Met and Asp, respectively, because these residues were found at the same positions in other subtypes. The two mutants, Nav 1.7 T1425M and Nav 1.7 I1426D, had a 16-fold and 5-fold increase in binding affinity for chiriquitoxin, respectively. CONCLUSIONS AND IMPLICATIONS: The reduced binding of chiriquitoxin to Nav 1.7 was attributed to its C11-OH and/or C12-NH2 , based on reported models for the TTX-VSSC complex. Chiriquitoxin is a useful tool for probing the configuration of the TTX binding site until a crystal structure for the mammalian VSSC is solved.
BACKGROUND AND PURPOSE: The development of subtype-selective ligands to inhibit voltage-sensitive sodium channels (VSSCs) has been attempted with the aim of developing therapeutic compounds. Tetrodotoxin (TTX) is a toxin from pufferfish that strongly inhibits VSSCs. Many TTX analogues have been identified from marine and terrestrial sources, although their specificity for particular VSSC subtypes has not been investigated. Herein, we describe the binding of 11 TTX analogues to human VSSC subtypes Nav 1.1-Nav 1.7. EXPERIMENTAL APPROACH: Each VSSC subtype was transiently expressed in HEK293T cells. The inhibitory effects of TTX analogues on each subtype were assessed using whole-cell patch-clamp recordings. KEY RESULTS: The inhibitory effects of TTX on Nav 1.1-Nav 1.7 were observed in accordance with those reported in the literature; however, the 5-deoxy-10,7-lactone-type analogues and 4,9-anhydro-type analogues did not cause inhibition. Chiriquitoxin showed less binding to Nav 1.7 compared to the other TTX-sensitive subtypes. Two amino acid residues in the TTX binding site of Nav 1.7, Thr1425 and Ile1426 were mutated to Met and Asp, respectively, because these residues were found at the same positions in other subtypes. The two mutants, Nav 1.7T1425M and Nav 1.7I1426D, had a 16-fold and 5-fold increase in binding affinity for chiriquitoxin, respectively. CONCLUSIONS AND IMPLICATIONS: The reduced binding of chiriquitoxin to Nav 1.7 was attributed to its C11-OH and/or C12-NH2 , based on reported models for the TTX-VSSC complex. Chiriquitoxin is a useful tool for probing the configuration of the TTX binding site until a crystal structure for the mammalian VSSC is solved.
Authors: H L Tan; M T Bink-Boelkens; C R Bezzina; P C Viswanathan; G C Beaufort-Krol; P J van Tintelen; M P van den Berg; A A Wilde; J R Balser Journal: Nature Date: 2001-02-22 Impact factor: 49.962
Authors: John V Mulcahy; Hassan Pajouhesh; Jacob T Beckley; Anton Delwig; J Du Bois; John C Hunter Journal: J Med Chem Date: 2019-05-07 Impact factor: 7.446
Authors: Quentin Coquerel; Claire Legendre; Jacinthe Frangieh; Stephan De Waard; Jérôme Montnach; Leos Cmarko; Joseph Khoury; Charifat Said Hassane; Dimitri Bréard; Benjamin Siegler; Ziad Fajloun; Harold De Pomyers; Kamel Mabrouk; Norbert Weiss; Daniel Henrion; Pascal Richomme; César Mattei; Michel De Waard; Anne-Marie Le Ray; Christian Legros Journal: Molecules Date: 2022-06-28 Impact factor: 4.927
Authors: Nicholas Denomme; April L Lukowski; Jacob M Hull; Margaret B Jameson; Alexandra A Bouza; Alison R H Narayan; Lori L Isom Journal: Neurosci Lett Date: 2020-02-27 Impact factor: 3.046
Authors: April L Lukowski; Nicholas Denomme; Meagan E Hinze; Sherwood Hall; Lori L Isom; Alison R H Narayan Journal: ACS Chem Biol Date: 2019-04-15 Impact factor: 5.100
Authors: H Pajouhesh; J T Beckley; A Delwig; H S Hajare; G Luu; D Monteleone; X Zhou; J Ligutti; S Amagasu; B D Moyer; D C Yeomans; J Du Bois; J V Mulcahy Journal: Sci Rep Date: 2020-09-09 Impact factor: 4.379
Authors: Gerard A Marchal; Arie O Verkerk; Rajiv A Mohan; Rianne Wolswinkel; Bastiaan J D Boukens; Carol Ann Remme Journal: Acta Physiol (Oxf) Date: 2020-05-27 Impact factor: 6.311